Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies"). Per the announcement, Retractable Technologies has been awarded a contract by the Department of Health and Human Services to supply a portion of the safety engineered syringes to be used in the United States' efforts to vaccinate the U.S. population against the H1N1 virus (swine flu).
"It is not often that a competitor's achievements are cause for excitement, but this is that rare case," stated Revolutions Medical CEO Ron Wheet. "Retractable Technologies has proven that major regulatory bodies are actively seeking and engaging suppliers of safety syringes, for efforts on a massive scale. Retractable Technologies' VanishPoint safety needle is indeed a quality product, but one against which we believe our Rev Vac safety syringe compares very favorably. Both have similar features, but the VanishPoint product relies on an additive metal spring that injects some uncertainty of performance, while our Rev Vac requires no additional parts and operates through a consistently reliable vacuum mechanism. Our vacuum is created by design when the plunger is drawn, ensuring predictable speed and ease of retraction."
Added Revolutions Medical President Tom O'Brien, "And likely as important to cost-sensitive agencies and hospitals, we will bring the Rev Vac to market at less than half the published cost of the VanishPoint safety needle. Cost is a function of design, parts count and manufacturing investment; the financial commitment we have made to engineering a patented design of such elegant simplicity allows us to outperform competitive products, while keeping production costs lower than our peers.
"This announcement confirms the magnitude of the opportunity before us, and we believe our product's competitive advantages will well position Revolutions Medical to pursue and win business of this kind."
Revolutions Medical is currently finalizing Rev Vac safety syringe production schedules, gearing up global distribution, and having discussions with potential corporate partners worldwide.